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Abstract
Background: Cancer stem cells (CSCs) are considered as the origin of tumor relapse. Here, we investigated the
effects of Fructus Viticis total flavonoids (FVTF) on the characteristics of lung cancer stem-like cells (LCSLCs) derived
from human small cell lung cancer NCI-H446 cell line and its potential mechanism.
Methods: Human small cell lung cancer NCI-H446 cell line was cultured in vitro. The CD133+ cells were sorted from
NCI-H446 cell line by magnetic separation.
The suspended culture with stem cell-conditioned medium was used to amplify CD133+ sphere-forming cells
(SFCs). The stem cell characteristics of CD133+ SFCs were evaluated using cell self-renewal capacity by tumor
sphere formation assay, migration and invasion capacity by Transwell assay, tumorigenicity by xenograft model in
nude mouse and cancer stem cell markers expression levels by western blot. The effects of FVTF on the properties
of LCSLCs were examined by tumorsphere formation assay and transwell chamber assay. The expression level of
p-Akt was determined by western blot analysis.
Result: CD133+ SFCs derived from human small cell lung cancer NCI-H446 cells exhibited stemness properties of
tumorsphere formation and tumorigenesis capacity comparing to the parental cells. FVTF relative selectively
inhibited the proliferation of LCSLCs, suppressed tumor sphere forming capacity and migration and invasion of
LCSLCs, and down-regulated the protein expression of stem cell markers (CD133, CD44 and ALDH1), self-renewal
associated transcription factors (Bmi1, Nanog and OCT4) and invasion associated transcription factors (Twist1 and
Snail1) in a dose-dependent manner. Moreover, we found that FVTF treatment could significantly decrease the
phosphorylation level of Akt in LCSLCs. Meanwhile, LY294002 and FVTF synergistically inhibited the characteristics of
LCSLCs.
Conclusion: FVTF inhibits the characteristics of LCSLCs through down-regulating expression of p-Akt.
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Background
Lung cancer is one of the most common malignancies
worldwide and it ranks as the most frequent cause of
cancer-related deaths especially in urban areas of China
[1, 2]. The most common subtypes of lung cancer are
non-small cell lung cancer (NSCLC) and small cell lung
cancer (SCLC). And the latter is the most aggressive form
of lung cancer, with a high invasive capacity and greater
tendency for development of early metastasis [3]. Despite
all kinds of conventional therapeutic regime applied in
clinical treatment, lung cancer has a dismal 5-year survival
rate due to failure of currently available therapeutic
approaches and finally resulting in disease relapse [4].
Researchers frequently attributes the therapy resist-
ance of lung cancer to cancer stem cells(CSCs) within
the tumors. Increasing evidence has indicated that many
types of solid cancer, including lung cancer, are origi-
nated from and maintained by a minor subpopulation of
CSCs [5, 6]. These cells possess the capacity of continu-
ous self-renewal, differentiation and initiating tumor for-
mation as well as show increased resistance to radiation
and chemotherapy. CSCs are considered as the origin of
tumor relapse.
Recently, various methods based on specific cell sur-
face markers, the capacity of cells to exclude membrane
permeable dyes or the ability of tumor sphere formation
for single cell in suspension in serum-free medium have
been used for CSCs isolation and characterization [7–9].
Similar to other solid tumors, several putative surface
markers for lung CSC(LCSCs) have been identified, in-
cluding CD133 and CD44 [6, 10–12]. Eramo et al. found
the existence of a rare population of undifferentiated
cells expressing CD133 in small cell and non-small cell
lung cancer for the first time. These minor population of
CD133+ tumorigenic cells able to self-renew and give
rise to an unlimited progeny of differentiated tumor cells
are named lung cancer stem cells (LCSCs) [10]. How-
ever, another study by Meng et al. found out that both
the CD133+ and CD133- subpopulations from SCLC
cells contain similar numbers of cancer stem cells, which
suggest that CD133 alone cannot be used as a stem cell
marker for the SCLC [7]. In addition, Jiang et al. also
demonstrated that Aldehyde dehydrogenase 1 (ALDH1)
is a tumor stem cell-associated marker in lung cancer
[8]. Taken together, although no certain specific cell
markers for LCSCs have been defined yet, we think that
the suspended culture with stem cell-conditioned
medium can be at least used as a crucial approach for
enrichment of LCSCs. Therefore, developing new
chemotherapy agents that can target these LCSCs has
profound implications for cancer chemoprevention and
therapy.
Fructus Viticis (Manjingzi is the Chinese name), the
dried ripe fruit of Vitex trifolia L. (family Verbenaceae),
is a traditional Chinese medicine possessing a broad
range of pharmacological activities [13–15]. Fructus
Viticis contains large amounts of flavonoids, including
casticin, luteolin, apigenin, isoorientin, hesperidin, isovi-
texin and so on [16–18]. Accumulating studies have sub-
stantiated the anti-tumor properties of these flavonoids
in a diverse range of human cancer cells and their xeno-
graft models in mice [19, 20]. FVTF(Fructus Viticis Total
Flavonoids), an independent innovation of our labora-
tory, is a candidate Chinese medicine preparation
extracted from Fructus Viticis (National invention appli-
cation No. ZL 201210591146.9).
In the present study, we obtained the CD133+ sphere-
forming cells (SFCs) from NCI-H446 cells by employing
CD133+ magnetic separation and stem cell-conditioned
medium culture method. Furthermore, we confirmed
the LCSLCs characteristic of SFCs by compared the self-
renewal capacity, stem cell markers expression levels,
and tumorigenicity of SFCs and non-sorting cells,
namely parental cells. The aims of this study were to in-
vestigate whether FVTF could inhibit the characteristics
of LCSLCs and the potential mechanisms involved.
Methods
Drugs and reagents
The Fructus Vititcis was purchased from Yuling Zhonggui
Pharmaceutical Company (Yuling, Guangxi province,
China). Prof. Bing-Qing Zhao (Department of Pharmacy,
Medical College of Hunan Normal University) identified
the specimens. A voucher specimen has been deposited in
the Department of Pharmacy, Medical College of Hunan
Normal University (No. MJZ-001). Fructus Viticis Total
Flavonoids(FVTF) was extracted and prepared from Fruc-
tus Viticis according to the patent specification (National
invention application of China No. ZL 201210591146.9),
present as brown powder. The measured amounts of total
flavonoids in drying FVTF were 53 % calculated based on
rutin.
DMEM medium(High glucose), DMEM/F12 medium,
fetal bovine serum, 0.25 % trypsin(containing EDTA) and
phosphate buffered saline (PBS) were purchased from
Hyclone(Logan, UT, USA). Recombination human
fibroblast growth factor (bFGF), epidermal growth fac-
tor (EGF) and B27 were purchased from eBioscience.
Hematoxylin and Eosin Staining Kit, Matrigel (BD Bio-
sciences, USA). Cell lysis buffer, trypan Blue, penicillin
and streptomycin (Invitrogen Life Technologies) and
bovine serum albumin were purchased from Hunan
Clonetimes Biotech Co., Ltd. (Changsha, Hunan). Human
insulin were purchased from Beijing Dingguo Changsheng
Biotechnology Co. Ltd. Mouse monoclonal antibodies
anti-CD44, ALDH1, Bmi1, Nanog, Oct4, Twist, Snail,
p-Akt (Ser473), Akt, β-actin were from Cell Signaling
Technology (Beverly, MA, USA).
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Cell culture
Human small cell lung cancer (SCLC) cell line NCI-
H446 was purchased from Keygen biotechnology Co.,
Ltd. (NanJing, China), and was maintained in DMEM
(High glucose) supplemented with 10 % fetal bovine
serum, 100 U/mL penicillin and 100 μg/mL strepto-
mycin in an incubator containing 5 % CO2 at 37 °C.
Magnetic separation of CD133+ cells
The CD133+ positive cells were sorted from NCI-H446
cell line using magnetic separation (Miltenyi Biotec,
Germany) according to the manufacturer’s instruction.
Briefly, a single-cell suspension was firstly prepared and
the cell number were determined before magnetic label-
ing. Cells were collected by centrifuge at at 300 × g for
10 min and the cell pellet were resuspended in 60 μL of
buffer per 107 total cells. 20 μL of FcR Blocking Reagent
and CD133 MicroBeads were added per 107 total cells,
respectively. After mixing well and incubation at 2-8 °C
for 15 min, cells were washed and resuspended up to107
cells in 500 μL of buffer. The cell suspension was finally
applied onto a MACS Column, and the unlabeled cells
(CD133−) and magnetically labeled cells (CD133+) were
collected repectively. Thereafter, the sorted CD133+ cells
were seeded in ultra-low attachment 6-well plates (Corning
Inc., NY, USA) for amplification culture with stem cell-
conditioned medium.
Flow cytometry analysis
The sorted CD133+ cells, CD133− cells and unsorted
parental NCI-H446 cells were washed with PBS, and
were adjusted to the single cell suspension at a density
of 1 × 105 cells/mL, respectively. Cells were incubated
with PE-conjugated anti-human CD133 antibody (Biole-
gend, San Diego, CA, United States) for 30 min at 4 °C
in the dark, and mouse IgG2b-PE was used as an isotype
control. Finally, The cell suspension was applied onto a
flow cytometry analysis of the percentage of CD133+
cells.
Tumor sphere formation assay
The self-renewal capacity of cells was evaluated using
suspension culture in ultra-low attachment 6-well plates
(Corning Inc., NY, USA) with stem cell-conditioned
medium [20]. Single cell suspensions were prepared with
stem cell-conditioned medium and were loaded into
ultra-low attachment 6-well plates (2 × 103cells/ml).
After culture for 6 days, the number of tumor spheres
formed were counted and pictured under a phase-
contrast microscope (Nikon Eclipse TE2000-S). The
sphere forming rate was calculated as the total number
of tumor spheres formed/the total number of cells inoc-
ulated × 100 %. For drug-intervention experiment, differ-
ent concentrations of FTVF were added to the medium
prior to cells were inoculated. For secondary sphere for-
mation assay, tumor spheres derived from CD133+ NCI-
H446 cells were digested and prepared into single cell
suspensions. After that, cells were seeded into ultra-low
attachment 6-well plates at a density of 1 × 103cells/mL,
and no drugs was added in the procedure of secondary
sphere formation assay.
MTT assay
Parental NCI-H446 cells and CD133+ SFCs were seeded
at a density of 5 × 103 cells/well in a 96-well plate pre-
coated with 0.6 % agarose, respectively. The procedure
for MTT assay and the calculation of relative cell prolif-
eration inhibition rate have been previously described
[19]. The IC50 value was calculated using the Prism soft-
ware (GraphPad Software, San Diego, CA).
In vitro cell migration and invasion assays
The migration and invasion assays were performed using
24-well uncoated or Matrigel (BD Biosciences, United
States) coated Transwell chambers with 8.0-μm pore
polycarbonate membranes (Corning Coster, Cambridge,
MA, USA) as previously described [21]. Briefly, 600 μL
DMEM with 10 % FBS was added to the 24-well culture
plate (lower chambers). Then the Transwell chambers
were inserted into the 24-well plate, and cells were re-
suspended in a serum and growth factor-free DMEM
and loaded into chambers (1 × 104 cells/100 μl). Follow-
ing incubation at 37 °C, cells that migrated or invaded to
the lower surface of the membrane were fixed and
stained with hematoxylin-eosin or Wright-Giemsa. Fi-
nally, the stained cells were digitally imaged and counted
under an optical microscope (OLYMPUS IX51, Japan).
For drug-intervention experiment, cells were pretreated
with different concentrations of FTVF for 24 h prior to
the transwell chamber assay.
Western blot analysis
Western blot procedures were performed as previously
described [22]. The following primary antibodies were
used: Mouse monoclonal antibodies anti-CD44, ALDH1,
Bmi1, Nanog, Oct4, Twist, Snail, p-Akt (Ser473) and
Akt. β-actin was used as an internal control. Signals
were detected using Enhanced chemiluminescence Kit
(Amersham Pharmacia Biotech Inc., Piscataway, NJ,
USA).
Nude mice tumorigenicity assay
The SPF male Balb/c-nu mice were obtained from the
Hunan Slac Jingda Laboratory Animal Co., Ltd. (Yueyang,
Hunan). All animal studies in this study were performed
according to the experimental animal breeding and use
guide of Hunan Laboratory Animal Management Com-
mittee after approved by the Ethical Committee of Hunan
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Normal University. 18 SPF male Balb/c-nu mice were ran-
domly devided into three groups (6/group). CD133+ cells
and parental cells in PBS were mixed 1:1 with Matrigel
(BD Biosciences, San Jose, CA) and were injected subcuta-
neously into the flanks of the animals, respectively. The
numbers of cells inoculated in three groups were 1 × 102,
1 × 103 and 1 × 104/mouse for CD133+ SFCs, and 1 × 104,
1 × 105 and 1 × 106/mouse for parental cells, respectively.
The animals were maintained in accordance with standard
guidelines for about 2 months for tumor appearance. The
size of tumor nodules were measured using an caliper,
and the volume was calculated using V (mm3) = L (the
longest diameter) ×W (the shortest diameter)2 × 0.5. At
the end of experiment, the tumors were excised, weighed
and divided into pieces to be fixed in neutral buffered for-
malin and embedded in paraffin and sectioned for a rou-
tine histological evaluation using hematoxylin and eosin
(H&E) staining or for immunohistochemical analysis of
CD44 and CD133.
Immunohistochemical examination
The xenografted tumor tissuses were fixed in 10 % forma-
lin, embedded in paraffin and sectioned for immunohisto-
chemical analysis. For immunohistochemical staining, the
deparaffinized sections were incubated with 3.3 % H2O2
for 10 min to block endogenous peroxidase activity. The
sections were then blocked with Tris Buffered Saline
(TBS) containing 5 % normal goat serum for 30 min. After
incubated with diluted corresponding primary antibodies
(1:200 for mouse anti-CD133 antibody and 1:250 for
mouse anti-CD44 antibody) and a secondary antibody,
the signals were detected using an EnVision system
(Dako, Carpinteria, CA, USA) and counterstained with
hematoxylin .
Statistics analysis
Results are shown as mean ± SD. Analysis of variance
was performed with SPSS 15.0 software for Windows
using one-way ANOVA and pair-wise comparison with t
test. P < 0.05 was considered statistically significant.
Results
Magnetic separation of CD133+ cells from NCI-H446 cell line
NCI-H446 cells grew anchorage-dependently in DMEM
supplemented with 10 % fetal bovine serum. After sorted
by CD133 microbeads separation system, the percent-
ages of CD133 expressing cells in unsorted parental
cells, CD133+ and CD133− subpopulation cells were ex-
amined by flow cytometry analysis. Results showed that
the percentages of CD133 expressing cells were 91.85 ±
2.17 %, 0.03 ± 0.01 % and 1.71 ± 0.29 % in CD133+,
CD133− subpopulation and parental cells respectively
(Fig. 1). The sorted CD133+ cells derived from NCI-
H446 cell line were further cultured for amplification in
stem cell-conditioned medium. And the generated
CD133+ SFCs were used for the following experiment.
CD133+ SFCs from NCI-H446 cell line exhibited lung
cancer stem cell characteristics
Figure 2a shows that sphere-forming rate of CD133+
SFCs was much higher than that of parental cells. More-
over, Fig. 2b shows that single cells dissociated from
CD133+ SFCs could form secondary tumor spheres con-
tinuously. These results suggested that CD133+ SFCs
possessed stronger self-renewal capacity. In line with
these findings, it was shown by western blotting that the
expression levels of self-renewal related transcription
factors (Bmi1, Nanog and Oct4) and stem cell markers
(CD44 and ALDH1) in CD133+ SFCs were much higher
than that of parental cells (Fig. 2c).
Considering that CSCs might play a vital role in the
early cancer metastasis, we next seek to examine the inva-
sion capacity of CD133+ SFCs and parental cells. Results
showed that CD133+ SFCs exhibited a higher invasion
capacity in vitro than parental cells. And western blot
Fig. 1 CD133 expression of CD133+, CD133− subpopulation cells
and parental NCI-H446 cells. a, control; b, parental NCI-H446 cells;
c, CD133+ subpopulation cells; d, CD133− subpopulation cells;
e, CD133 expression in the above four cells described by histogram.
*P < 0.05 vs control, # P < 0.05 vs parental NCI-H446 cells
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results also showed that compared to parental cells,
CD133+ SFCs expressed a higher level of EMT related
transcription factors Twist1 and Snail1 (Fig. 2d and e).
Furthermore, the in vivo tumorigenicity experiment
results showed that 1 × 103 CD133+ SFCs cells could ini-
tiated tumor formation 18 days after inoculated Balb/c-
Fig. 2 CD133+ SFCs from NCI-H446 cell line exhibited higher self-renewal capacity compared to that of parental cells. a, The sphere-forming rate
of CD133+ SFCs and parental cells (PC). b, Tumor sphere formation by single cell dissociated from CD133+ SFCs derived from SCLC NCI-H446 cell
line (200 ×magnification). c, The expression levels of self-renewal related transcription factors (Bmi1, Nanog and Oct4) and stem cell markers were
compared between CD133+ SFCs and parental NCI-H446 cells at 48 h. d, In vitro invasion capacity were compared between CD133+ SFCs and
parental NCI-H446 cells (400 × magnification). e, The expression levels of invasion related transcription factors (Twist1 and Snail1) were compared
between CD133+ SFCs and parental NCI-H446 cells at 48 h
Cao et al. BMC Complementary and Alternative Medicine  (2016) 16:364 Page 5 of 12
nu mice, as compared to 31 days of tumorigenic latent
period for 1 × 105 parental cells (Table 1, Fig. 3a). Mean-
while, staining results revealed that the transplanted tu-
mors derived from CD133+ SFCs and parent cells
exhibited the similar histological morphology (Fig. 3b).
These results indicated that CD133+ SFCs showed
higher tumorigeic potential than parent cells. And the
immunohistochemical results also showed that the fre-
quency of CD133 and CD44 expressing cells in tumor
tissues derived from CD133+ SFCs were significantly
higher than that derived from parental cells (Fig. 3c).
These findings fully supported our hypothesis that the
enrichment of LCSLCs contributed to the high tumori-
geic potential of CD133+ SFCs. Taken together, all the
above findings strongly suggested that CD133+ SFCs
possessed CSCs characteristics, and could be defined as
LCSLCs.
FVTF inhibits self-renewal of LCSLCs
Self-renewal property is the key feature of CSCs, which
enables CSCs to initiate and maintain tumors conti-
niously. Thus exploring new chemotherapy drugs that
can target the self renewal pathway of CSCs would be
extremely important for cancer therapy. Results in this
study showed that FVTF (0.1, 1, 3, 10, 30 μg/mL) could
preferentially inhibit the proliferation of LCSLCs in a
concentration-dependent manner, and the IC50 is
0.7 μg/mL, as compared to an IC50 of 3.7 μg/mL for
parental cells (Fig. 4a). Moreover, the tumor sphere for-
mation assays results also demonstrated that FVTF
(0.5, 1.0, 2.0 μg/mL) could both significantly decrease
the primary and secondary tumor sphere forming rates
of LCSLCs (Fig. 4b and c). These findings indicated
that FVTF could suppress the self-renewal capacity of
LCSLCs. In accordance with the above findings, the re-
sults of western blot analysis also revealed that FVTF
(0.5、1.0、2.0 μg/mL) decreased expression level of
the self-renewal related transcription factors Bmi1,
Nanog and Oct4 in a concentration-dependent manner
(Fig. 4d).
Table 1 Comparison of tumor formation ability of CD133+ SFCs
and parental NCI-H446 cells in Balb/c-nu mice (n = 6)
Cell type Cells inoculated (n) Tumor incidence(n/6) Latency(d)
PCs 1 × 104 0/6 –
1 × 105 3/6 31
1 × 106 6/6 23
CD133+ SFCs 1 × 102 0/6 –
1 × 103 4/6 18
1 × 104 6/6 11
PCs parental NCI-H446 cells, CD133+ SFCs CD133+ tumor sphere forming cells
derived from NCI-H446 cell line
Fig. 3 CD133+ SFCs from NCI-H446 cell line exhibited higher in vivo tumorigeic capacity compared to that of parental cells. a, In vivo tumorigeic
capacity was compared between SFCs and parental NCI-H446 cells. Up: Balb/c-nu mice were inoculated subcutaneously with 1.0 × 105 parental
cells in the left fore leg, and no xenograft was observed 4 weeks after inoculation. Down: Balb/c-nu mice were inoculated subcutaneously with
1.0 × 103 SFCs in the right fore leg, and xenograft formed 4 weeks after inoculation. b, The transplanted tumors derived from SFCs and parental
cells exhibited the similar histological morphology(HE staining) (100 ×magnification). c, The expression levels of stem cell markers (CD133 and
CD44) were compared between xenografts formed by SFCs and parental NCI-H446 cells (100 ×magnification)
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FVTF decreases stem cell markers expression of LCSLCs
In order to investigate the effects of FVTF on stem
cell markers expression of LCSLCs, we examined the
expression level of CD133, CD44 and ALDH using
Flow cytometry or western blot analysis. As shown in
Fig. 4e and f, FVTF decreased stem cell markers
expression of LCSLCs CD133, CD44 and ALDH1 in a
concentration-dependent manner.
FVTF inhibits migration and invasion of LCSLCs in vitro
Furthermore, we are tempted to examine the effects of
FVTF on migration and invasion capacity of LCSLCs in
Fig. 4 FVTF inhibits self-renewal of LCSLCs. a, FVTF selectively inhibited the proliferation of LCSLCs in a concentration-dependent manner. b and c,
FVTF significantly decrease the primary and secondary tumor sphere forming rates of LCSLCs. d, FVTF decreased expression level of the self-renewal
related transcription factors Bmi1, Nanog and Oct4 in a concentration-dependent manner at 48 h. e, FVTF decreased the expression of stem cell
markers CD 133 of LCSLCs in a concentration-dependent manner as analyzed by Flow cytometry analysis at 48 h. ISC: Isotype control, SFC: CD133+
sphere forming cells derived from NCI-H446 cells; F, FVTF decreased the expression of stem cell markers CD 44 and ALDH1 of LCSLCs in a
concentration-dependent manner as analyzed by western blotting at 48 h
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vitro. Transwell results showed that FVTF (0.5, 1.0,
2.0 μg/mL) inhibited migration and invasion of LCSLCs
in vitro in a dose-dependent manner (Fig. 5a and b). In
line with these findings, It was found that the invasion
related transcription factors Twist1 and Snail1 of
LCSLCs were significantly down-regulated after treat-
ment with FVTF of different concentrations (Fig. 5c).
FVTF inhibits LCSLCs characteristics through
down-regulation of p-Akt
It has been reported that PI3K-Akt pathway could pro-
mote self-renewal capacity of Hematopoietic stem cells
(HSCs) through regulating polycomb group protein in-
cluding Bmi1. Consequently, we are tempted to examine
the phosphorylation level of AKT in LCSLCs. Western
blot analysis results showed that activation of AKT was
highly elevated in LCSLCs compared to that in parental
cells (Fig. 6a). And FVTF (0.5, 1.0, 2.0 μg/mL) treatment
could significantly decrease the phosphorylation level of
Akt in LCSLCs (Fig. 6b). Futhermore, a PI3K specific in-
hibitor LY294002 was used in the following study. As
shown in Fig. 6c, LY294002 of different concentrations
could efficiently decrease the p-Akt level of LCSLCs de-
rived from NCI-H446 cells. We also found that down-
regulated expression of p-Akt by LY294002 significantly
inhibited self-renewal capacity of LCSLCs (Fig. 6d).
Moreover, results showed that LY294002 (5.0 μM) could
efficiently decreased FVTF(1.0 μg/mL) inhibited sphere
forming rate (Fig. 6e) and the invasion cell rate (Fig. 6f )
of LCSLCs to a lower level, accompanied by further
decreased expressions of self renewal and invasion re-
lated transcription factors of LCSLCs (Fig. 6g and h). In
summary, these findings indicated that the constitutively
activation of Akt was involved in maintaining self-
renewal of LCSLCs, and decreased phosphorylation level
of Akt contributed to the FVTF inhibited stem cell char-
acteristics of LCSLCs.
Discussion
Despite all kinds of efforts exploited to combat lung can-
cer, this disease remains the most frequent cause of
cancer-related deaths in China. It is now generally ac-
cepted that LCSLCs were the determining tumorigenic
cells responsible for lung cancer initiation, development,
metastasis and relapse after chemotherapy. Therefore,
targeted eradication of LCSLCs is extremely vital for im-
proving the prognosis or even recovery of lung cancer.
In the present study, we isolated, enriched and ob-
tained the CD133+ SFCs from human lung cancer NCI-
H446 cells, by CD133+ magnetic separation and stem
cell-conditioned medium suspension culture method.
The following results confirmed that this subpopulation
of cells exhibited higher in vitro self renewal, invasion
and tumorigenicity capacity over parental cells, accom-
panied by an upregulated expression level of stem cell
markers, self-renewal and invasion related transcription
factors. Collectively, these SFCs exerted stem-like cell
characteristics and were defined as LCSLCs.
Increasing new emerging data have reported that tran-
scription factors Bmi1, Nanog and Oct4 have been
Fig. 5 FVTF inhibited migration and invasion of LCSLCs in vitro. a and b, FVTF (0.5, 1.0, 2.0 μg/mL) inhibited migration and invasion of LCSLCs in
vitro in a dose-dependent manner (200 ×magnification). c, FVTF decreased expression levels of invasion related transcription factors Twist1 and
Snail1 of LCSLCs in a concentration-dependent manner
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implicated in regulating self-renewal and multi-
directional differentiation potential of CSCs and adult
stem cells. Park IK et al. has reported that Bmi1, a mem-
ber of the polycomb group proteins, is essential for
maintenance of adult self-renewing haematopoietic stem
cells [23]. Another study by Abdouh M et al. also re-
vealed that PcG proteins are involved in Glioblastoma
multiforme (GBM) tumor growth and required to sus-
tain cancer initiating stem cell renewal [24]. Nanog and
Oct4 are the core transcription factors that maintaining
the self-renewal and pluripotency of embryonic stem
cells [25–28]. It has been reported that coexpression of
Oct4 and Nanog promotes metastasis of lung adenocar-
cinoma by inducing cancer stem cell-like properties and
epithelial-mesenchymal transdifferentiation [29]. In this
study, we found that Bmi1, Nanog and Oct4 were highly
expressed in SFCs derived from NCI-H446 cells com-
pared to that in parental cells, as confirmed by western
Fig. 6 FVTF inhibits LCSLCs characteristics through down-regulation of p-Akt. a, The expression levels of phosphorylated AKT were compared
between SFCs and parental NCI-H446 cells. b, FVTF decreased phosphorylation levels of Akt in LCSLCs in a concentration-dependent manner.
c, LY294002 down-regulated phosphorylation levels of Akt in LCSLCs in a concentration-dependent manner. d, LY294002 significantly decreased
the tumor sphere forming rate of LCSLCs. e, LY294002 significantly enhanced the inhibition effects of FVTF on tumor sphere formation capacity
of LCSLCs. f, LY294002 significantly enhanced the inhibition effects of FVTF on cell invasion capacity of LCSLCs. g, LY294002 significantly enhanced
the down-regulation of self-renewal related transcriptional factors by FVTF in LCSLCs. h, LY294002 significantly enhanced the down-regulation of
invasion related transcriptional factors by FVTF in LCSLCs
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blot analysis. It indicated that the SFCs possessed self re-
newal and pluripotency properties.
It is generally accepted that most cancer related-
deaths are attributed to the local invasion and distal mi-
gration, but not the primary tumor itself [30, 31]. CSCs
were considered to play a pivotal role in the early metas-
tasis of many kinds of human malignant tumors includ-
ing lung cancer. In our study, it was demonstrated by
Transwell assays that SFCs derived from NCI-H446 cells
exhibted higher invasion capacity in vitro than parental
cells. These results revealed that SFCs possessed high in-
vasion and metastatic potential. The invasion related
protein Snail was one member of the zinc-finger tran-
scription factor Snail superfamily. It has been reported
that Snail can directly or indirectly mediated epithelial-
mesenchymal transition (EMT) which results in tumor
cell invasion and metastases. In clinical practice, overex-
pression of Snail is associated with poor prognosis and
increased invasioness in several type of cancer patients
[32–34]. Twist1, which belonged to the basic Helix-
Loop-Helix (bHLH) transcription factor family, is a
highly evolutionally conserved transcription factor firstly
found in Drosophila and initially involved in embryo de-
velopment by contributing to cell migration. A study
from Mikheeva et al. has reported that TWIST1 pro-
motes invasion through activation of mesenchymal mo-
lecular and cellular changes in human glioblastoma [35].
Li et al. has revealed that Twist1 depletion completely
blocked the mesenchymal transformation induced by
Adriamycin [36]. Our previous study also found that
Twist signaling involved in maintaining self-renewal and
invasion properties of liver cancer stem cells. In this
study, we showed that the EMT-related transcription
factors Snail and Twist1 were highly expressed in SFCs
as compared to that in parental cells. Although no gene
expression regulation measures were further taken, we
have reasons to speculate that the high invasion capacity
of SFCs may be related to its high expression level of
Snail1 and Twist.
Since increasing studies have proved that there exists a
plenty of active compounds with anti-cancer properties
in some phytomedicines, extracting and isolating anti-
cancer agents from naturally-occurring plants becomes
one of the main approaches for new anti-tumor drugs
discovery. In the present study, we demonstrated that
the candidate Chinese medicine preparation FVTF could
relative selectively inhibit the proliferation and self-
renewal, and suppress migration and invasion of LCSLCs
in vitro. In agreement with above findings, we also found
that FVTF down-regulated the protein expression of
stem cell markers (CD133, CD44 and ALDH1), self-
renewal associated transcription factors (Bmi1, Nanog
and OCT4) and invasion associated transcription factors
(Twist1 and Snail1) in a dose-dependent manner.
Furthermore, we demonstrated that the inhibitory effects
of FVTF on LCSLCs characteristics appeared to be me-
diated through down-regulating expression of p-Akt.
Akt, also known as protein kinase B(PKB), is a multi-
functional serine-theonine protein kinase involved in a
variety of biological functions in cells. A recent study
has reported that Akt activation in Hair follicle stem
cells (HF-SCs) results in increased tumor development
and malignant transformation [37]. Chen et al. showed
that Akt could phosphorylate Oct4 at threonine 228 to
accelerate its degradation. And Akt mediated phosphor-
ylation of special AT-rich sequences binding protein 1
(SATB1) played a key role in inhibiting Nanog expres-
sion [38]. Another study by Wang et al. found that
AKT/β-catenin/Snail signaling pathway is mechanistic-
ally involved in acquisition of cancer stem cell-like prop-
erties and EMT features in cisplatin-resistant A549 cells
[39]. In this study, we also showed that the constitutively
activation of Akt was involved in maintaining self-
renewal of LCSLCs. And the use of FVTF or LY294002
could significantly decrease the phosphorylation level of
Akt in LCSLCs. Interestingly, we also found that
LY294002 could act alone or synergize with FVTF to
suppress the characteristics of LCSLCs. Therefore, it is
reasonable to speculate that FVTF may inhibited the
phosphorylation of Akt by a pathway different from the
way that LY294002 acted in.
Taken together, our results have demonstrated that
FVTF can inhibit characteristics of LCSLCs derived from
NCI-H446 cell line. And the mechanisms is probably
associated with down-regulating expression of p-Akt in
LCSLCs, which lead to downregulation of the expres-
sions of stem cell markers, self-renewal associated tran-
scription factors and invasion associated transcription
factors. However, based on the limitation of conducting
these experiments in a single cell line derived LCSLCs,
future efforts would be made toward confirming the
therapeutic effects of FVTF in more cell lines as well as
in animal model.
Conclusions
FVTF inhibits characteristics of lung cancer stem-like
cells through down-regulating expression of p-Akt.
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